Biovance Capital Partners SCR
Venture capitalLisbon · Seed–Series A · 16 people tracked
Investment thesis
Biovance Capital invests in disruptive, early-stage biopharma companies across Europe, supporting the development of transformational therapies across all modalities and therapeutic areas. The firm invests in seed and Series A rounds and typically brings additional co-investors to add value and mitigate risk. It works closely with entrepreneurs and scientists to build leading companies delivering novel medical treatments to patients in need. Biovance leverages a broad European network of research institutes, incubators and accelerators to source a rich pipeline of potential investments. Its Fund I, described as the first biotech-dedicated fund in Portugal's biomedical ecosystem, is backed by the European Investment Fund among other investors.
Source: firm website, verified Aug 3, 2026.
Team · 16 people
from the firm's websiteFrequently asked questions
- What stage does Biovance Capital Partners SCR invest at?
- Biovance Capital Partners SCR invests at the Seed, Series A stages.
- What sectors does Biovance Capital Partners SCR focus on?
- Biovance Capital Partners SCR focuses on Biotech, Healthtech, Medical Devices.
- Where is Biovance Capital Partners SCR located?
- Biovance Capital Partners SCR is headquartered in Lisbon, PT.
Images
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Granatus Ventures is a venture capital firm that backs startups worldwide leveraging Armenia's potential as an emerging technology hub.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
Sunstone Life Science Ventures is an independent European venture capital firm focused on early-stage life science companies developing novel therapeutics for humans.

















